Hexima Ltd (HXL) AI Stock Analysis

• Market Cap: AU$2.17M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): -1.63
• Revenue Growth: N/A
• EPS Growth: -26.67%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 167,039,630
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.02
• Price to Book (P/B): 1.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: ―

Hexima Ltd's stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and negative cash flows. The technical analysis suggests a bearish market sentiment, while valuation metrics reflect the company's unprofitable status. The absence of earnings call data and corporate events means these factors do not influence the score. Overall, the company needs to focus on improving its financial health to enhance stock performance.

Hexima Ltd Business Overview & Revenue Model

Company Description

Hexima Ltd (HXL) is a biotechnology company focused on the research and development of plant-derived proteins for agricultural and pharmaceutical applications. The company's core products include proprietary protein-based solutions designed to enhance crop protection and improve human health. Hexima operates primarily in the agricultural biotech and pharmaceutical sectors, leveraging advanced genetic engineering technologies to deliver innovative solutions that address pressing industry needs.

How the Company Makes Money

Hexima Ltd generates revenue through the commercialization of its proprietary plant-derived protein technologies. The company's key revenue streams include the sale of licensed products to agricultural producers and pharmaceutical companies, as well as collaboration and licensing agreements with industry partners. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. Additionally, Hexima may engage in research and development collaborations that provide financial support and access to new markets. The company also benefits from government grants and subsidies aimed at promoting innovation in biotechnology.

Hexima Ltd Financial Statement Overview

Summary

Hexima Ltd faces significant financial challenges, with consistent operating losses and negative cash flows. While the balance sheet is supported by strong equity and a solid cash position, the company struggles with profitability and sustainable revenue growth. Strategic improvements in revenue generation and cost management are essential for future stability.

Income Statement

Hexima Ltd has experienced negative revenue growth and consistent losses over the past years. Net profit margin and other profitability metrics are negative, indicating ongoing financial challenges. The company needs to improve revenue generation and cost management to stabilize its financial health.

Balance Sheet

The balance sheet shows a strong equity position with no debt, resulting in a favorable debt-to-equity ratio. However, the company has been unable to generate positive returns on equity due to persistent losses, affecting its ability to create shareholder value.

Cash Flow

Operating cash flow has been negative, reflecting operational inefficiencies. Although Hexima Ltd has maintained a strong cash position, free cash flow remains negative, indicating challenges in generating cash from operations despite limited capital expenditures.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	0.00	0.00	1.48M	5.81M	4.08M	88.18K
Gross Profit	0.00	0.00	1.47M	5.67M	3.93M	-176.81K
EBITDA	-549.11K	-995.54K	-3.08M	-15.21M	-10.34M	-5.19M
Net Income	-955.58K	-933.87K	-1.92M	-10.02M	-6.87M	-3.63M
Balance Sheet
Total Assets	1.68M	2.27M	2.96M	10.75M	8.58M	12.71M
Cash, Cash Equivalents and Short-Term Investments	1.64M	2.23M	2.19M	3.96M	3.42M	9.14M
Total Debt	0.00	0.00	0.00	0.00	32.00K	64.00K
Total Liabilities	61.89K	248.67K	174.45K	6.19M	5.53M	3.39M
Stockholders Equity	1.61M	2.02M	2.78M	4.57M	3.05M	9.32M
Cash Flow
Free Cash Flow	-321.19K	-161.90K	-1.76M	-9.76M	-5.79M	-2.10M
Operating Cash Flow	-321.19K	-161.90K	-1.76M	-9.76M	-5.79M	-2.10M
Investing Cash Flow	48.76K	98.00K	38.97K	-1.80K	-903.00	-1.74K
Financing Cash Flow	0.00	100.00K	-3.66K	10.34M	7.90M	1.46M

Hexima Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Neutral
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HXL, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, equal to the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 1.67 is Positive, neither overbought nor oversold. The STOCH value of -150.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HXL.

Hexima Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
PYC	50 Neutral	AU$746.57M	―	-112.97%	―	―	-84.82%
PIQ	48 Neutral	AU$69.50M	―	-131.55%	―	12.53%	-11.04%
HXL	40 Underperform	AU$2.17M	―	-45.96%	―	―	-26.67%
BIT	36 Underperform	AU$2.65M	―	-119.28%	―	―	64.10%

Hexima Ltd Corporate Events

Hexima Limited Reports Quarterly Financials with Strategic Focus

Hexima Limited, an Australian company listed on the ASX, reported its financial activities for the quarter ending March 31, 2025. The company closed the quarter with a cash balance of $1.55 million, using $87,000 in net cash for operating activities, primarily for compliance costs and professional fees. The report highlights Hexima’s ongoing evaluation of strategies to benefit the company and its shareholders, with a focus on maintaining financial stability and operational efficiency.

Hexima Limited Reports Increased Losses and Decline in Net Tangible Assets

Hexima Limited, an Australian company, reported a 6% increase in its loss from ordinary activities after tax, amounting to $406,473 for the half-year ending December 31, 2024. The company did not declare any dividends during this period, and its net tangible assets per ordinary security decreased from 1.52 cents to 0.97 cents, indicating a decline in financial performance.